Abstract：【Objective】To investigate the effect of concurrent chemoradiotherapy combined with dendritic cell-cytokine-induced natural killer (DC-CIK) cell immunotherapy on the prognosis and tumor marker levels of non-small cell lung cancer (NSCLC). 【Methods】Seventy-two NSCLC patients were randomly divided into the control group and the observation group,with 36 cases in each group. The control group was treated with TP regimen (paclitaxel + cisplatin) combined with intensity-modulated radiotherapy (IMRT),while the observation group was treated with DC-CIK cellular immunotherapy on the basis of treatment in the control group. The curative effect,peripheral blood T lymphocyte subsets (CD3+,CD4+,CD8+,CD4+/CD8+),serum microRNA-137 (miR-137),microRNA-29a (miR-29a) and serum tumor markers were compared between the two groups before and after treatment. Changes in the levels of substances [carbohydrate antigen 125 (CA-125),carcinoembryonic antigen (CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)] were compared as well. The incidence of adverse reactions in the two groups was observed. 【Results】The objective remission rate (RR) of the observation group was 94.44% (34/36),which was higher than that of the control group of 77.78% (28/36) (P<0.05). After treatment,CD3+,CD4+,CD4+/CD8+ in the two groups were higher than those before treatment (P<0.05),and CD8+ was lower than those before treatment (P<0.05). And after treatment,CD3+,CD4+,CD4+/CD8+ in the observation group were higher than those in the control group (P<0.05),there was no significant difference in CD8+ compared with the control group (P>0.05). After treatment,the levels of miR-137,miR-29a,CA-125,CEA,and CYFRA21-1 in the two groups were lower than those before treatment (P<0.05); and the levels of each index in the observation group were lower than those in the control group after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Concurrent chemoradiotherapy combined with DC-CIK cellular immunotherapy can improve the curative effect of NSCLC patients,down-regulate the expression of miR-137 and miR-29a,improve the immune function and serum tumor markers of patients. And the risk of adverse reactions is low,which is worthy of clinical promotion.
2022, Vol. 39 
